CERTIFICATION
Lukas Biomedical's introduction of immunocellular therapy for cancer has been published in top international medical journals such as The Lancet (2000) and Gastroenterology (2015). The results of the Phase III clinical trials for liver cancer patients (n=150 and n=230) demonstrated that a single treatment course could effectively prolong recurrence-free survival time and increase overall survival rates.
In accordance with the General Data Protection Regulation (GDPR) enforced by the European Union, we are committed to protecting your personal data and providing you with control over it.
By clicking "Accept All," you consent to our use of cookies to enhance your experience on this website, assist us in analyzing website performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Confirm," you agree to adopt the current settings.
Privacy preferences
In accordance with the General Data Protection Regulation (GDPR) enforced by the European Union, we are committed to protecting your personal data and providing you with control over it.
By clicking "Accept All," you consent to our use of cookies to enhance your experience on this website, assist us in analyzing website performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Confirm," you agree to adopt the current settings.
Manage preferences
Necessary cookie
The website cannot function without these cookies, and you cannot disable them in our system. These cookies are typically set in response to actions you take, such as setting your privacy preferences, logging in, or filling out forms. You can set your browser to block or alert you about these cookies, but this may cause some parts of the website to not work properly.
